ArticleCurrent stem cell research & therapy2025
Regenerative Potential of Umbilical Cord Blood-derived Stromal Cells along with Phytosterol Campesterol in Wound Healing of a Rat Model.
Article in Current stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMesenchymal stem cells derived from umbilical cord blood (UCB-MSCs) have a well-known role in fastening the wound healing process due to their less immune rejection, anti-inflammatory effects, and their role in cellular growth. Campesterol is a nutritional phytosterol with extensive health values and a competitor of cholesterol in the blood. Campesterol shares some anti-inflammatory effects via its regulation of inflammatory markers by inhibiting the proinflammatory cytokines (including TNF-α, TGF-β1, and IL-6) levels.
methodThe purpose of this study was to assess the ameliorative role of combined therapy (campesterol and UCB-MSCs) in wound healing without immune rejection. The study comprised both invitro and in-vivo experiments. In-vitro analysis included assessments of the cell viability of campesterol on UCBMSCs using MTT, crystal blue, trypan blue, and cell scratch assays. For in-vivo trials, superficial burn wounds were created on Sprague Dawley rats to evaluate the effects of campesterol, UCB-MSCs, and their combination on healing outcomes. Tissue regeneration progress in the wound vicinity was assessed using H&E staining and ELISA (inflammatory and growth markers) analysis.
resultResults of in-vitro experiments indicated that campesterol at concentrations of 10μg, 20μg, and 30μg demonstrated the most efficient cell viability. Moreover, a 30ug dose of campesterol along with UCBMSCs was further applied, leading to smooth and uncomplicated healing in the animal models. H&E staining showed nearly normal skin tissue while hematological and biochemical markers were near to control. Serum levels of tissue growth promoter factors, including VEGF and collagen- 3, were higher, and pro-inflammatory markers (such as TGF-β1, TNF-α, and IL-6) were lower at the same time.
conclusionThe results of the combined (MSCs and campesterol) therapy showed enhanced wound healing abilities. However, further studies are recommended to explore new aspects of this promising therapeutic approach of UCB-MSCs along with steroid derivative campesterol.
Indexed as
Identifiers
40183274What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.